NASDAQ:RADX Radiopharm Theranostics (RADX) Stock Price, News & Analysis $4.25 -0.34 (-7.41%) Closing price 04:00 PM EasternExtended Trading$4.28 +0.03 (+0.59%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Radiopharm Theranostics Stock (NASDAQ:RADX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RADX alerts:Sign Up Key Stats Today's Range$4.19▼$4.5650-Day Range$4.14▼$5.1052-Week Range$3.62▼$16.25Volume63,135 shsAverage Volume129,779 shsMarket Capitalization$50.19 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingModerate Buy Company Overview Radiopharm Theranostics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology. The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types. Radiopharm Theranostics collaborates with academic centers and contract development and manufacturing organizations to advance candidates from preclinical studies through clinical trials, with an emphasis on safety, efficacy and scalable production. Headquartered in Alpharetta, Georgia, Radiopharm Theranostics conducts operations in the United States and is positioning itself for expansion into select international markets. Its management team brings together professionals with deep expertise in radiopharmaceutical chemistry, nuclear medicine and oncology drug development, underscoring the company’s commitment to advancing next-generation diagnostic and therapeutic solutions.AI Generated. May Contain Errors. Read More Radiopharm Theranostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreRADX MarketRank™: Radiopharm Theranostics scored higher than 74% of companies evaluated by MarketBeat, and ranked 168th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingRadiopharm Theranostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialRadiopharm Theranostics has a consensus price target of $16.00, representing about 276.5% upside from its current price of $4.25.Amount of Analyst CoverageRadiopharm Theranostics has only been the subject of 1 research reports in the past 90 days.Read more about Radiopharm Theranostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Radiopharm Theranostics are expected to grow in the coming year, from ($1.80) to ($1.22) per share.Price to Book Value per Share RatioRadiopharm Theranostics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.34% of the float of Radiopharm Theranostics has been sold short.Short Interest Ratio / Days to CoverRadiopharm Theranostics has a short interest ratio ("days to cover") of 1.04, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Radiopharm Theranostics has recently decreased by 57.55%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRadiopharm Theranostics does not currently pay a dividend.Dividend GrowthRadiopharm Theranostics does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentRadiopharm Theranostics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.MarketBeat Follows3 people have added Radiopharm Theranostics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Radiopharm Theranostics insiders have not sold or bought any company stock.Percentage Held by InstitutionsRadiopharm Theranostics has minimal institutional ownership at this time.Read more about Radiopharm Theranostics' insider trading history. Receive RADX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Radiopharm Theranostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RADX Stock News HeadlinesRadiopharm Theranostics ADR (RADX): Inside the Clinical ProgramsApril 28, 2026 | insidermonkey.comRadiopharm Theranostics Reports Business UpdateApril 23, 2026 | globenewswire.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 6 at 1:00 AM | Brownstone Research (Ad)Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer ...April 20, 2026 | finance.yahoo.comRadiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain MetastasesApril 16, 2026 | markets.businessinsider.comRadiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26April 16, 2026 | msn.comRadiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60April 9, 2026 | msn.comRadiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical TrialApril 8, 2026 | markets.businessinsider.comSee More Headlines RADX Stock Analysis - Frequently Asked Questions How have RADX shares performed this year? Radiopharm Theranostics' stock was trading at $5.22 on January 1st, 2026. Since then, RADX shares have decreased by 18.6% and is now trading at $4.25. How were Radiopharm Theranostics' earnings last quarter? Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) released its quarterly earnings data on Wednesday, January, 28th. The company reported ($1.58) EPS for the quarter. The business had revenue of $0.46 million for the quarter. Who are Radiopharm Theranostics' major shareholders? Top institutional investors of Radiopharm Theranostics include Hsbc Holdings PLC (0.52%). How do I buy shares of Radiopharm Theranostics? Shares of RADX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings1/28/2026Today5/06/2026Fiscal Year End6/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RADX's financial health is in the Yellow zone, according to TradeSmith. RADX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:RADX CIK1949257 Webwww.radiopharmtheranostics.com Phone61-3-9824-5254FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Radiopharm Theranostics$16.00 High Price Target$16.00 Low Price Target$16.00 Potential Upside/Downside+276.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick RatioN/A Sales & Book Value Annual Sales$2.35 million Price / Sales21.36 Cash FlowN/A Price / Cash FlowN/A Book Value$3.52 per share Price / Book1.21Miscellaneous Outstanding Shares11,810,000Free FloatN/AMarket Cap$50.19 million OptionableN/A Beta1.28 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:RADX) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredMilitary ‘Dark Energy’ to Power AIWhen it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...Altimetry | SponsoredNobody's Asking Where The SpaceX Money Comes FromWhen SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...Americas Gold Company | SponsoredRevealed: The World’s First Trillion-Dollar RobotJensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...Weiss Ratings | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Radiopharm Theranostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
